We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

The recent decision by US authorities to limit the use of Johnson & Johnson’s (J&J) coronavirus vaccine over concerns about a rare blood-clotting disorder will fuel hesitancy about its use in other parts of the world and may jeopardise SA’s vaccine manufacturing ambitions, Medical Research Council president Glenda Gray warned on Monday.  

The US Food and Drug Administration (FDA) announced on Friday that people should get immunised with mRNA vaccines made by Pfizer or Moderna instead of J&J’s shot, unless they had medical reasons not to, did not want an mRNA jab, or mRNA shots were not available. Citing data previously flagged by other US authorities, the FDA said the risks of the J&J shot outweighed the benefits for adults who could get an alternative...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now